REG3A and diabetes mellitus: While clinical indications to date have focused on diabetes and ALF, REG3A’s broader biological properties, including epithelial repair, preservation of intestinal barrier integrity, and modulation of innate immunity and the gut microbiota, point to its therapeutic promise in other conditions, such as mucosal injury and chronic inflammatory diseases.